AI Article Synopsis
- The study evaluated the impact of percutaneous needle biopsy (PNB) and bronchoscopic biopsy (BB) on tumor spread (STAS) in patients with stage I non-small cell lung cancer (NSCLC).
- Following a careful matching process, the findings indicated no significant increase in STAS occurrence between biopsy groups and non-biopsy counterparts.
- Additionally, both PNB and BB did not affect recurrence-free survival (RFS) or overall survival (OS) after surgery, suggesting that these preoperative biopsies are safe in this context.
Article Abstract
Background: Percutaneous needle biopsy (PNB) and bronchoscopic biopsy (BB) are widely used in the preoperative diagnosis of pulmonary nodules, but whether PNB or BB may cause tumor spread through air spaces (STAS) has not been reported.
Methods: 433 postoperative patients with pathological stage I non-small cell lung cancer (NSCLC) from January 2015 to December 2018 at our hospital were enrolled and divided into PNB group (n = 40), BB group (n = 48) and non-biopsy group (n = 345). The PNB and BB groups were matched using propensity score matched (PSM) separately from the non-biopsy group, after which the effects of PNB and BB on STAS, recurrence-free survival (RFS) and overall survival (OS) were assessed.
Results: After PSM for 9 confounding factors (gender, age, smoking history, tumor site, scope of surgery, pathology type, stage, maximum tumor diameter and postoperative treatment), 38 cases in the PNB group were successfully matched with 38 cases in the non-biopsy group and 28 cases in the BB group were successfully matched with 28 cases in the non-biopsy group. After PSM, there was no significant difference in the incidence of STAS between the PNB and non-biopsy groups (42.1% vs. 34.2%, P > 0.05) and between the BB and non-biopsy groups (42.9% vs. 46.4%, P > 0.05). The results after PSM showed no significant effect of both PNB and BB on RFS and OS after radical surgery (P > 0.05).
Conclusion: Preoperative biopsy in patients with stage I NSCLC has not been shown to increase the occurrence of STAS, nor postoperative recurrence and death.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339177 | PMC |
| http://dx.doi.org/10.1186/s12890-022-02090-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Celiac disease in North America: What is the current practice of pediatric gastroenterology providers?
JPGN Rep
August 2024
Department of Pediatrics, Division of Gastroenterology and Nutrition, McMaster Children's Hospital McMaster University Hamilton Ontario Canada.
Objectives: While guidelines exist for the diagnosis and management of pediatric celiac disease (CeD), current practices in North America are not well-described. This study aimed to explore current practice patterns to identify gaps and direct future clinical, training and research initiatives.
Methods: A 23-item survey designed by the Celiac Disease Special Interest Group was distributed electronically to its members.
Article Synopsis
- - Celiac disease (CD) is an immune disorder triggered by gluten in those genetically predisposed, with worldwide prevalence around 1%, typically diagnosed through antibody testing followed by an invasive biopsy.
- - This study analyzed the medical records of 94 patients diagnosed with CD through biopsy, focusing on the levels of anti-tTGA antibodies and their correlation with the severity of lesions (Marsh grading).
- - Findings suggest that high serum levels of anti-tTGA antibodies (greater than 10 times the upper limit of normal) can reliably indicate severe CD lesions (Marsh grade 3) without the need for a biopsy.
Opportunities for Improving Biopsy and Non-Biopsy-Based Diagnosis of Celiac Disease.
Gastroenterology
June 2024
Department of Medicine, Columbia University Irving Medical Center, New York, New York; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
The accumulating data regarding a non-biopsy diagnosis of celiac disease has led to its adoption in certain scenarios, although debate on whether and when to use non-biopsy criteria in clinical practice is ongoing. Despite the growing popularity and evidence basis for a biopsy-free approach to diagnosis in the context of highly elevated serologies, there will continue to be a role for a biopsy in some groups. This review summarizes the current evidence supporting a non-biopsy approach and arguments supporting continued reliance on biopsy, and focuses on opportunities to improve both approaches.
View Article and Find Full Text PDFDoes an excision of needle bone biopsy tract affect the prognosis in patients with primary bone tumor?
J Orthop
February 2024
Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Background: Opinion remains divided as to whether excision of needle biopsy tract is beneficial and affect the prognosis. The aim of the study was to compare the outcomes in patients of primary malignant bone tumor who had undergone surgery with or without biopsy tract excision.
Methods: From January 2017 to June 2020, 240 patients with primary malignant bone tumors who underwent percutaneous needle biopsy followed by surgery were included.
Safety and efficacy of remimazolam compared with midazolam during bronchoscopy: a single-center, randomized controlled study.
Sci Rep
November 2023
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Article Synopsis
- Remimazolam is an ultra-short-acting benzodiazepine that shows quicker recovery and sedation compared to midazolam during bronchoscopy, according to a limited number of studies.
- In a prospective randomized study, remimazolam resulted in significantly shorter times to peak sedation and full alertness than midazolam, along with higher satisfaction ratings among patients not undergoing biopsies.
- While the overall adverse effects were similar between both drugs, midazolam required more antidote administrations, suggesting that remimazolam may be a safer option for sedation in bronchoscopic procedures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!